Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. (RAPT) is a clinical-stage biopharmaceutical leader developing oral therapies for oncology and inflammatory diseases. This news hub provides investors and industry professionals with verified updates on the company's scientific advancements and corporate developments.
Comprehensive Resource: Track all official announcements including clinical trial milestones, regulatory submissions, financial results, and strategic partnerships. Our curated collection ensures efficient access to material developments affecting RAPT's position in immunology-focused drug discovery.
Key Coverage Areas: Stay informed about CCR4-targeting therapies like tivumecirnon (FLX475) and inflammatory disease candidates such as zelnecirnon (RPT193). Receive updates on FDA communications, research collaborations, and pipeline expansion efforts without speculative commentary.
Strategic Monitoring: Bookmark this page for real-time access to primary source materials. Professionals relying on precision medicine updates will find this centralized repository essential for tracking RAPT's progress in addressing unmet medical needs through innovative immunology approaches.
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical have entered into an exclusive license agreement for JYB1904 (RPT904), a clinical-stage anti-IgE antibody. RAPT obtains worldwide rights excluding China, Hong Kong, Macau, and Taiwan for a $35 million upfront payment, up to $672.5 million in milestone payments, and high single-digit to low-double digit royalties.
RPT904 is being developed as a potential improvement over omalizumab (Xolair®), targeting the same epitope but with an extended half-life. Jemincare's Phase 1 study showed good safety profile and a half-life more than twice that of omalizumab. RAPT plans to initiate a Phase 2b trial in food allergy in the second half of 2025, while Jemincare is conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China.
RAPT Therapeutics (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company, reported its third quarter 2024 financial results. Net loss for Q3 2024 was $18.4 million, a significant improvement from the $31.4 million loss in Q3 2023. Research and development expenses decreased to $13.3 million from $27.0 million in Q3 2023, mainly due to lower development costs for zelnecirnon, tivumecirnon, and early-stage programs, as well as reduced personnel and lab supply expenses. General and administrative expenses also saw a slight reduction to $6.4 million from $6.9 million. The company implemented a workforce reduction in July 2024, affecting 47 employees (40% of the workforce), incurring $0.9 million in restructuring charges. For the nine months ended September 30, 2024, net loss was $76.6 million, down from $85.9 million in the same period of 2023. As of September 30, 2024, RAPT held $97.9 million in cash and marketable securities.
RAPT Therapeutics (Nasdaq: RAPT) announced the termination of its zelnecirnon (RPT193) program following FDA clinical holds on two Phase 2 trials in asthma and atopic dermatitis. The holds were implemented in February 2024 due to a serious adverse event of liver injury requiring transplant in one patient. No other liver toxicity or treatment-related serious adverse events were reported in other participants. The company plans to advance next-generation CCR4 compounds with improved safety margins and expects to identify a new candidate in first half 2025, while pursuing in-licensing opportunities for clinical-stage assets.
RAPT Therapeutics (Nasdaq: RAPT) reported financial results for Q2 2024. Key points include:
- Net loss of $27.7 million in Q2 2024, up from $25.3 million in Q2 2023
- R&D expenses increased to $22.6 million in Q2 2024 from $21.6 million in Q2 2023
- G&A expenses remained unchanged at $6.7 million for both Q2 2024 and Q2 2023
- Cash and equivalents of $114.8 million as of June 30, 2024
- Workforce reduction of 40% (47 people) announced on July 16, 2024
The company continues to analyze data from Phase 2 trials of zelnecirnon in atopic dermatitis and asthma, which were closed early due to FDA clinical holds in February.
RAPT Therapeutics, Inc. reported its financial results for the first quarter of 2024, maintaining a solid cash position of $141.6 million. The company decided to close and unblind its Phase 2b clinical trial of zelnecirnon in atopic dermatitis and its Phase 2a trial in asthma due to a serious adverse event of liver failure. Despite challenges, the company remains optimistic about the data collected and is working towards completing the analysis in the third quarter of the year.
FAQ
What is the current stock price of Rapt Therapeutics (RAPT)?
What is the market cap of Rapt Therapeutics (RAPT)?
